Patients Whose Doctors Recommend AREDS2 Supplements Show Slower AMD Lesion Growth

Why It Matters

The findings demonstrate that AREDS2 can actively slow existing AMD damage, not just lower the risk of advanced disease, influencing prescribing habits and patient outcomes. This adds a therapeutic dimension to a widely used over‑the‑counter supplement, potentially preserving vision for millions of seniors.

Key Takeaways

• AREDS2 recommendation cut hypertransmission defect by 6.9% in one year
• Retinal atrophy biomarker fell 8.4% with physician‑prescribed AREDS2
• Ellipsoid zone loss decreased 6.1% among patients advised to supplement
• Study used AI‑driven OCT analysis on 607 intermediate AMD patients
• Results support AREDS2 for slowing existing AMD lesion progression

Pulse Analysis

Age‑related macular degeneration remains the leading cause of vision loss among older adults, and clinicians have long relied on the AREDS2 formulation to reduce the risk of progression to advanced disease. While numerous trials have confirmed its preventive benefits, the question of whether AREDS2 can mitigate damage already present has lingered. Recent advances in retinal imaging and AI analytics now enable researchers to track subtle structural changes over time, offering a more granular view of disease dynamics than ever before.

The ARVO‑presented study leveraged a unique multimodal dataset compiled by Character Biosciences, integrating longitudinal clinical records, high‑resolution 2‑D and 3‑D OCT scans, and patient genetics. By applying AI‑based image segmentation to 607 intermediate‑AMD eyes, investigators quantified six lesion‑growth biomarkers and focused on the three that demonstrated the greatest response to supplementation. Over twelve months, patients with a documented physician recommendation for AREDS2 experienced double‑digit percentage reductions in hypertransmission defects, retinal atrophy, and ellipsoid zone loss—metrics directly linked to visual function decline. The control cohort, lacking a formal recommendation, showed no comparable shifts, underscoring the potential additive effect of clinician guidance.

For ophthalmologists and eye‑care providers, these results reinforce the value of proactive supplement counseling as part of a comprehensive AMD management plan. The data suggest that consistent AREDS2 intake may buy patients additional years of functional vision, a compelling proposition for a demographic increasingly focused on quality of life. Pharmaceutical and nutraceutical firms may also see an opportunity to position AREDS2 as a disease‑modifying agent, prompting further real‑world studies and possibly influencing insurance coverage policies. As longer‑term follow‑up data emerge, the eye‑care community will gain clearer insight into how sustained supplementation impacts the trajectory of macular degeneration.